PMID- 29299357
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 8
IP  - 6
DP  - 2017 Dec
TI  - The correlations between serum amphiregulin and other clinicopathological factors 
      in colorectal cancer.
PG  - 980-984
LID - 10.21037/jgo.2017.08.15 [doi]
AB  - BACKGROUND: Amphiregulin (AREG) is one of the epidermal growth factor receptor 
      (EGFR) ligands and plays the important roles in tumor progression and metastasis. 
      Upregulation of AREG in colorectal cancer (CRC) tissues has been shown to 
      correlate with depth of tumor invasion, nerve invasion and liver metastasis. We 
      sought to investigate a correlation of serum AREG in CRC with clinicopathological 
      parameters. METHODS: Patients with CRC receiving treatment at King Chulalongkorn 
      Memorial Hospital during August 2013 to March 2014 were enrolled. We collected 
      baseline serum prior to start any therapy and stored till analysis. Serum AREG 
      was measured by ELISA. The correlation between each clinicopathological 
      characteristic and serum AREG was analysed. RESULTS: There were 120 patients with 
      CRC including 78 patients (65.0%) with stage I-III and 41 patients (34.2%) in 
      stage IV or recurrent disease. In stage IV or recurrent group, the median level 
      of serum AREG was 31.55 pg/mL, which was higher than those of stage I-III group, 
      15.48 pg/mL, P=0.001. The serum AREG higher than 25 pg/mL (high serum AREG) was 
      significantly correlated with liver and peritoneal metastasis (P<0.001). 
      Additionally, high serum AREG was significantly correlated with more poor 
      differentiated/mucinous histological grade (P=0.014), distant metastasis 
      (P=0.001), lymphovascular invasion (P=0.016) and perineural invasion (P<0.001). 
      CONCLUSIONS: High serum AREG was associated with advanced diseases and poor 
      pathologic factors in CRC. It is potentially a prognostic marker in CRC.
FAU - Chayangsu, Chawalit
AU  - Chayangsu C
AD  - Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Chualalongkorn University, Bangkok, Thailand.
FAU - Khunsri, Siriporn
AU  - Khunsri S
AD  - Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Chualalongkorn University, Bangkok, Thailand.
FAU - Sriuranpong, Virote
AU  - Sriuranpong V
AD  - Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Chualalongkorn University, Bangkok, Thailand.
FAU - Tanasanvimon, Suebpong
AU  - Tanasanvimon S
AD  - Division of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, Chualalongkorn University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC5750193
OTO - NOTNLM
OT  - Serum amphiregulin
OT  - biomarker
OT  - colorectal cancer (CRC)
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2018/01/05 06:00
MHDA- 2018/01/05 06:01
PMCR- 2017/12/01
CRDT- 2018/01/05 06:00
PHST- 2018/01/05 06:00 [entrez]
PHST- 2018/01/05 06:00 [pubmed]
PHST- 2018/01/05 06:01 [medline]
PHST- 2017/12/01 00:00 [pmc-release]
AID - jgo-08-06-980 [pii]
AID - 10.21037/jgo.2017.08.15 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2017 Dec;8(6):980-984. doi: 10.21037/jgo.2017.08.15.